

Special Issue

Evolving Role of the Thoracic Oncologic Surgeon in the Era of Molecular and Immune-Targeted Therapies for Lung Cancer

Message from the Guest Editor

The advent of molecular-targeted therapy and immune checkpoint inhibitors has revolutionized the treatment of patients with advanced-stage lung cancer over the past 10 years. Recent promising studies have now begun to investigate the use of immunotherapy and drug-targeted oncogenic driver mutations in patients with operable lung cancer. With the expansion of these treatments to the neoadjuvant setting, it will be critical for the thoracic oncologic surgeon to understand and incorporate preoperative molecular testing and define clinical algorithms aimed at reducing surgical risk in patients who have undergone treatment with molecular targeted therapy and immunotherapy. This Special Edition of the *Cancers* journal will highlight original research and comprehensive reviews related to preoperative tumor molecular characterization, as well as the incorporation of targeted therapy and/or immunotherapy in the treatment of patients with lung cancer undergoing curative resection.

Guest Editor

Dr. Matthew D. Taylor

Division of Thoracic Surgery, Department of Surgery, Penn State Milton S. Hershey Medical Center, Hershey, PA 17033, USA

Deadline for manuscript submissions

closed (15 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/126406

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)